ArticleCritical care (London, England)2015
To beta block or not to beta block; that is the question.
Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 37 citations in OpenAlex.
- Efficacy and Safety of Esmolol in Treatment of Patients with Septic Shock.Chinese medical journal · 2016Trial
- Association between heart rate and mortality in patients with septic shock: an analysis revealed by time series data.BMC infectious diseases · 2024Article
- Impact of beta-blocker usage on delirium in patients with sepsis in ICU: a cross-sectional study.Frontiers in medicine · 2024Article
- Mitigating the stress response to improve outcomes for older patients undergoing emergency surgery with the addition of beta-adrenergic blockade.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2022Review
- The influence of esmolol on right ventricular function in early experimental endotoxic shock.Physiological reports · 2018Article
- Microvascular effects of intravenous esmolol in patients with normal cardiac function undergoing postoperative atrial fibrillation: a prospective pilot study in cardiothoracic surgery.Critical care (London, England) · 2017Observational
- Outpatient beta-blockers and survival from sepsis: Results from a national cohort of Medicare beneficiaries.American journal of surgery · 2017Article
- [Heart in sepsis : Molecular mechanisms, diagnosis and therapy of septic cardiomyopathy].Der Anaesthesist · 2017Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fast-acting β-1 blocker esmolol has been the center of attention since the landmark article by Morrelli and colleagues suggesting that, in patients with sepsis, reducing heart rate by administering esmolol can result in a survival benefit. However, the use of esmolol for the treatment of sepsis and the underlying mechanism responsible for this benefit remain controversial. This commentary discusses the study by Jacquet-Lagrèze and colleagues, who in a pig model of sepsis tested the hypothesis that administration of esmolol to reduce heart rate may correct sepsis-induced sublingual and gut microcirculatory alterations which are known to be associated with adverse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.